Lọc tín hiệu

VDP

VIDIPHA Central Pharma
PharmaceuticalsHOSE
Same sector:AGPAMPBCHBCPBIOCDPCNCDANDBDDBM
31.000
−4,02%
2026-10-19

Fundamental Analysis

37 / 100BRubric: Manufacturing
Quarterly resultsRelative Valuation
CriterionLatest Q EPS growth (YoY)Avg EPS growth, last 3 (YoY)Quarters with EPS growthRevenue growth (YoY)Gross margin change (pp, YoY)Net margin change (pp, YoY)Return on Equity (TTM)Financial health (Debt/Equity)Valuation (P/E vs 5-yr median)Revenue (bn)Rev YoYNPAT (bn)NPAT YoYP/E5-Year Median P/EP/E vs. 5-Year Median
Value-27.9%-19.6%0 / 3-12.0%+9.74 pp+1.30 pp+8.2%0.2812.10233−12,0%19,1+4,6%12.1011.03+9,7%
Pts00001280128
Valuation annotation:Price: 31.000 (close price on 2026-10-19)EPS (TTM): 2.563

Financial charts

1.Revenue & growth

VND bn225Q2/26

1.Revenue & growth

VND bn225Q2/26

2.Profit & growth

VND bn19,1Q2/26

3.Profit mix (Penman)

VND bn82,0Q2/26

4.Margins & cost structure

%27.1%Q2/26

5.Returns & cash cycle

% · days10.5%Q2/26

6.Earnings quality & cash

VND bn-40,5Q2/26

7.Asset structure

VND bn1.076Q2/26

8.Funding & debt health

VND bn · times1.076Q2/26

9.Revenue backlog

VND bn1,26Q2/26

10.Valuation

times · %15,9×Q2/26

11.EPS growth & dilution warning (CANSLIM)

VND per share; growth in %864Q2/26
Adjusted EPS growth, latest quarter
4.6%
Average adjusted EPS growth, 3 quarters
-8.8%
Quarters at 25%+ growth
0/3
Share dilution rate, 1 year
0.0%

Source: vnstockData through Q2/26